CoChat

Bupropion and naltrexone for smoking cessation: A double‐blind randomized placebo‐controlled clinical trial

Open access
Mooney, ME, Schmitz, JM, Allen, S, Grabowski, J, Pentel, P, Oliver, A, Hatsukami, DK · 2016 · Clinical Pharmacology & Therapeutics
Cited by 28

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Combination of non‐nicotine pharmacotherapies has been underexamined for cigarette smoking cessation. A randomized, double‐blind, parallel‐group double‐dummy study evaluated two medications, bupropion (BUP) and naltrexone (NTX), in treatment‐seeking cigarette smokers (N= 121) over a 7‐week treatment intervention with 6‐month follow‐up. Smokers were randomized to either BUP (300 mg/day) + placebo (PBO) or BUP (300 mg/day) + NTX (50 mg/day). The primary outcome was biochemically verified (saliva cotinine, carbon monoxide) 7‐day, point‐prevalence abstinence. BUP + NTX was associated with significantly higher point‐prevalence abstinence rates after 7‐weeks of treatment (BUP + NTX, 54.1%; BUP + PBO, 33.3%),P= 0.0210, but not at 6‐month follow‐up (BUP + NTX, 27.9%; BUP + PBO, 15.0%),P= 0.09. Continuous abstinence rates did not differ,P= 0.0740 (BUP + NTX, 26.2%; BUP + PBO, 13.3%). Those receiving BUP + NTX reported reduced nicotine withdrawal,P= 0.0364. The BUP + NTX combination was associated with elevated rates of some side effects, but with no significant difference in retention between the groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cpt.402

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Mooney, M., Schmitz, J., Allen, S., Grabowski, J., Pentel, P., Oliver, A., & Hatsukami, D.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2016-06-20
Volume
100
Issue
4
Pages
344-352
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2399413811
Cited by
28
References
12
FWCI
2.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.